Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TBio-6517 |
Synonyms | |
Therapy Description |
TBio-6517 is an engineered vaccinia virus that expresses the Flt3 ligand, an antibody targeting CTLA4, and the cytokine IL-12, which may lead to immune activation and increased anti-tumor immune response, and decreased tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TBio-6517 | RIVAL-01 | TBio-6517 is an engineered vaccinia virus that expresses the Flt3 ligand, an antibody targeting CTLA4, and the cytokine IL-12, which may lead to immune activation and increased anti-tumor immune response, and decreased tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |